CD274 and non-small cell lung carcinoma: Taken together, these results indicate that our BCTscore model can predict the overall survival of NSCLC patients treated with anti–PD-L1 atezolizumab therapy at 12 weeks on-treatment to decide whether treatment can be terminated or alternative treatment plans should be devised.